Start with the actual product
A familiar ingredient name can hide a very different product. Before comparing a sermorelin program, write down the formulation, route and dispensing pharmacy. These details make it possible to ask a specific question: has this particular finished medicine been reviewed by the FDA? A discussion about the ingredient’s history is not an answer about the product in your shipment.
FDA states that compounded drugs are not FDA-approved; the agency does not review their safety, effectiveness or quality before marketing. Compounding can meet a medical need, but that does not remove its risks. Read FDA’s explanation of compounded-drug risks.
The Geref history has a specific scope
In a March 2013 notice, FDA determined that the specified Geref injections had not been withdrawn from sale for reasons of safety or effectiveness. The notice describes historical uses for childhood growth hormone deficiency with growth failure and for evaluating pituitary growth hormone secretion. It also explains the implications for potential abbreviated drug applications. See the original Federal Register notice.
Our reading is deliberately narrow: this historical determination is not an approval of every current sermorelin formulation, every route or every advertised adult wellness use. When an offering invokes Geref, ask the clinician to explain exactly which part of that history is relevant to your proposed care.
Keep approval, suitability and quality separate
Approval status is one question. Whether a treatment is appropriate for your circumstances is another. Pharmacy quality and the clarity of the instructions are further questions. A reassuring answer in one category should not close the conversation in the others. FDA’s compounding questions and answers provides context for why medicines may be compounded.
Ask the prescriber why this formulation is proposed, what alternatives were considered, and how the evidence relates to your goal. Ask the pharmacy what information will accompany the medicine and whom to contact about its condition on arrival. You do not need to resolve a regulatory question yourself to request a plain-language explanation.
Leave with a written answer
A useful consultation produces something more concrete than “the ingredient has been around for years.” Request the product name, its compounded status, the pharmacy’s identity and the next follow-up step in writing. Save these alongside your cost estimate so that future shipments and charges can be compared with the original plan. Ask for clarification whenever the name on a later shipment differs from what you expected.
Our provider notebook describes published offers; it does not certify a pharmacy or determine personal eligibility. Use the consultation-question builder to take these questions with you, and the three-month planner to understand the financial commitment separately.
Sources linked alongside the relevant discussion. This is educational editorial reading, not a clinical assessment or personal treatment recommendation.